ArticleEuropean heart journal2026
Cardiac α4β2 nicotinic receptors as a therapeutic target for fatal ventricular arrhythmias.
Article in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
BACKGROUND AND
aimsFatal ventricular tachyarrhythmias (FVTs) are a major cause of sudden cardiac death globally. Despite their clinical importance, current antiarrhythmic therapies remain constrained by limited efficacy and proarrhythmic risks. Although endogenous cardiac cholinergic signalling contributes to electrophysiological regulation, the therapeutic potential of targeting ventricular α4β2 nicotinic acetylcholine receptors (nAChRs), a pivotal component of this system, for FVT treatment remains to be elucidated.
methodsA pharmacological screen identified positive allosteric modulators (PAMs) of α4β2 nAChRs as possessing antiarrhythmic properties. Through structure-based design, salvage-1 was developed and its efficacy and safety profile were evaluated in rodent, porcine, and human ex vivo heart models of FVTs. The underlying mechanism was investigated using patch-clamp electrophysiology, high-resolution optical mapping, and molecular dynamics simulations.
resultsPharmacological screening validated the potentiation of α4β2 nAChRs as a promising antiarrhythmic strategy. Structure-guided development yielded salvage-1, a PAM that selectively engages Phe312 and Phe316 on the α4 subunit to stabilize the receptor in an open-channel state. Across rodent, porcine, and human ex vivo heart models of FVTs, salvage-1 consistently prevented arrhythmogenesis and rapidly restored sinus rhythm. Mechanistically, salvage-1 enhanced acetylcholine-gated currents, selectively improved conduction velocity in injured myocardium, and suppressed re-entry, without compromising electrophysiology in healthy tissue.
conclusionsThis study identifies ventricular α4β2 nAChRs as a druggable target for FVTs and introduces salvage-1 as a first-in-class therapeutic candidate, thereby establishing a new direction for the pharmacological therapy of cardiac arrhythmias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.